schliessen

Filtern

 

Bibliotheken

Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients

OBJECTIVE: Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients.RESEARCH DESIGN AND METHODS: A nested case-control study was performed in a coho... Full description

Journal Title: Diabetes Care 01/01/2011, Vol.34(1), pp.129-131
Main Author: Monami, M.
Other Authors: Colombi, C. , Balzi, D. , Dicembrini, I. , Giannini, S. , Melani, C. , Vitale, V. , Romano, D. , Barchielli, A. , Marchionni, N. , Rotella, C. M. , Mannucci, E.
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0149-5992 ; E-ISSN: 1935-5548 ; DOI: http://dx.doi.org/10.2337/dc10-1287
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: crossref10.2337/dc10-1287
title: Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
format: Article
creator:
  • Monami, M.
  • Colombi, C.
  • Balzi, D.
  • Dicembrini, I.
  • Giannini, S.
  • Melani, C.
  • Vitale, V.
  • Romano, D.
  • Barchielli, A.
  • Marchionni, N.
  • Rotella, C. M.
  • Mannucci, E.
subjects:
  • Medicine
ispartof: Diabetes Care, 01/01/2011, Vol.34(1), pp.129-131
description: OBJECTIVE: Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients.RESEARCH DESIGN AND METHODS: A nested case-control study was performed in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched control subjects from the same cohort.RESULTS: During a median follow-up of 75.9 months, 112 case patients who developed incident cancer and were compared with 370 control subjects. A significantly lower proportion of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity, glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25-0.85], P = 0.014 and 0.75 [0.39-1.45], P = 0.40, respectively).CONCLUSIONS: The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients.
language: eng
source:
identifier: ISSN: 0149-5992 ; E-ISSN: 1935-5548 ; DOI: http://dx.doi.org/10.2337/dc10-1287
fulltext: fulltext
issn:
  • 01495992
  • 0149-5992
  • 19355548
  • 1935-5548
url: Link


@attributes
ID348863517
RANK0.07
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.2337/dc10-1287
sourceidcrossref
recordidTN_crossref10.2337/dc10-1287
sourceformatXML
sourcesystemPC
pqid822362874
display
typearticle
titleMetformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
creatorMonami, M. ; Colombi, C. ; Balzi, D. ; Dicembrini, I. ; Giannini, S. ; Melani, C. ; Vitale, V. ; Romano, D. ; Barchielli, A. ; Marchionni, N. ; Rotella, C. M. ; Mannucci, E.
ispartofDiabetes Care, 01/01/2011, Vol.34(1), pp.129-131
identifier
languageeng
source
lds4120110101
descriptionOBJECTIVE: Metformin is associated with reduced cancer-related morbidity and mortality. The aim of this study was to assess the effect of metformin on cancer incidence in a consecutive series of insulin-treated patients.RESEARCH DESIGN AND METHODS: A nested case-control study was performed in a cohort of 1,340 patients by sampling, for each case subject, age-, sex-, and BMI-matched control subjects from the same cohort.RESULTS: During a median follow-up of 75.9 months, 112 case patients who developed incident cancer and were compared with 370 control subjects. A significantly lower proportion of case subjects were exposed to metformin and sulfonylureas. After adjustment for comorbidity, glargine, and total insulin doses, exposure to metformin, but not to sulfonylureas, was associated with reduced incidence of cancer (odds ratio 0.46 [95% CI 0.25-0.85], P = 0.014 and 0.75 [0.39-1.45], P = 0.40, respectively).CONCLUSIONS: The reduction of cancer risk could be a further relevant reason for maintaining use of metformin in insulin-treated patients.
subjectMedicine;
version7
lds50peer_reviewed
links
openurl$$Topenurl_article
thumbnail
0$$TPCamazon_thumb
1$$TPCgoogle_thumb
openurlfulltext$$Topenurlfull_article
addlink$$Uhttp://exlibris-pub.s3.amazonaws.com/aboutCrossref.html$$EView_CrossRef_copyright_notice
search
creatorcontrib
0Monami, M.
1Colombi, C.
2Balzi, D.
3Dicembrini, I.
4Giannini, S.
5Melani, C.
6Vitale, V.
7Romano, D.
8Barchielli, A.
9Marchionni, N.
10Rotella, C. M.
11Mannucci, E.
titleMetformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
general
0English
110.2337/dc10-1287
2CrossRef
sourceidcrossref
recordidcrossref10.2337/dc10-1287
issn
001495992
10149-5992
219355548
31935-5548
rsrctypearticle
addtitleDiabetes Care
searchscope
0crossref_rest
1CrossRef
2Crossref
3crossref
scope
0crossref_rest
1CrossRef
2Crossref
3crossref
lsr402010201112012901
lsr4120110101
lsr4220101229
lsr4320110101
lsr442010
lsr452010201110012701
tmp012
tmp022
creationdate2011
startdate20110101
enddate20110101
citationpf 129 pt 131 vol 34 issue 1
lsr30VSR-Enriched:[pqid, description, subject]
sort
titleMetformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
authorMonami, M. ; Colombi, C. ; Balzi, D. ; Dicembrini, I. ; Giannini, S. ; Melani, C. ; Vitale, V. ; Romano, D. ; Barchielli, A. ; Marchionni, N. ; Rotella, C. M. ; Mannucci, E.
creationdate20110101
lso0120110101
facets
frbrgroupid8501948072549601953
frbrtype5
languageeng
creationdate2011
prefilterarticles
rsrctypearticles
creatorcontrib
0Monami, M.
1Colombi, C.
2Balzi, D.
3Dicembrini, I.
4Giannini, S.
5Melani, C.
6Vitale, V.
7Romano, D.
8Barchielli, A.
9Marchionni, N.
10Rotella, C. M.
11Mannucci, E.
jtitleDiabetes Care
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Monami
1Colombi
2Balzi
3Dicembrini
4Giannini
5Melani
6Vitale
7Romano
8Barchielli
9Marchionni
10Rotella
11Mannucci
aufirst
0M.
1C.
2D.
3I.
4S.
5V.
6A.
7N.
8C. M.
9E.
au
0Monami, M.
1Colombi, C.
2Balzi, D.
3Dicembrini, I.
4Giannini, S.
5Melani, C.
6Vitale, V.
7Romano, D.
8Barchielli, A.
9Marchionni, N.
10Rotella, C. M.
11Mannucci, E.
atitleMetformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
jtitleDiabetes Care
stitleDiabetes Care
risdate20110101
adddate
020101229
12010201112012901
220110101
32010
42010201110012701
volume34
issue1
spage129
epage131
pages129-131
issn0149-5992
eissn1935-5548
formatjournal
genrearticle
ristypeJOUR
doi10.2337/dc10-1287
lad012
citing
0$$t=2$$K1=2006$$K2=01495992$$K3=10.2337/diacare.29.02.06.dc05-1558$$K4=29$$K5=2$$K6=254$$K7=diabetes care$$K15=bowker$$K16=bowker$$K18=bowker
1$$t=2$$K1=2005$$K2=09598138$$K3=10.1136/bmj.38415.708634.F7$$K4=330$$K5=7503$$K6=1304$$K7=bmj
2$$t=2$$K1=2009$$K2=01495992$$K3=10.2337/dc08-2175$$K4=32$$K5=9$$K6=1620$$K7=diabetes care
3$$t=2$$K1=2010$$K2=01495992$$K3=10.2337/dc10-0666$$K4=33$$K5=7$$K6=1674$$K7=diabetes care$$K15=giovannucci$$K16=giovannucci$$K18=giovannucci
4$$t=2$$K1=2009$$K2=0732183X$$K3=10.1200/JCO.2009.19.6410$$K4=27$$K5=20$$K6=3297$$K7=journal of clinical oncology
5$$t=2$$K1=2009$$K2=00085472$$K3=10.1158/0008-5472.CAN-09-0418$$K4=69$$K5=16$$K6=6539$$K7=cancer research$$K15=kisfalvi$$K16=kisfalvi$$K18=kisfalvi
6$$t=2$$K1=2002$$K2=01495992$$K3=10.2337/diacare.25.12.2133$$K4=25$$K5=12$$K6=2133$$K7=diabetes care$$K15=wulffele$$K16=wulffele$$K18=wulffele
7$$t=2$$K1=2010$$K2=01495992$$K3=10.2337/dc10-0476$$K4=33$$K5=9$$K6=1997$$K7=diabetes care
8$$t=2$$K1=1994$$K2=08954356$$K3=10.1016/0895-4356(94)90129-5$$K4=47$$K5=11$$K6=1245$$K7=journal of clinical epidemiology$$K15=charlson$$K16=charlson$$K18=charlson
9$$t=2$$K1=2009$$K2=13510088$$K3=10.1677/ERC-09-0087$$K4=16$$K5=4$$K6=1103$$K7=endocrine related cancer
10$$t=2$$K1=2006$$K2=00085472$$K3=10.1158/0008-5472.CAN-06-1500$$K4=66$$K5=21$$K6=10269$$K7=cancer research
11$$t=2$$K1=2009$$K2=0732183X$$K3=10.1200/JCO.2009.25.4110$$K4=27$$K5=35$$K6=e259$$K7=journal of clinical oncology
12$$t=2$$K1=2009$$K2=01495992$$K3=10.2337/dc08-9025$$K4=32$$K5=1$$K6=193$$K7=diabetes care
date2011-01-01